Using a strategy based on network pharmacological disease target analysis and computerized compound-target seeking, we focused on the cyclin-dependent kinase (CDK) family, especially CDK1, as a target of TIZ for its anti-GBM function. The gene discussed is CDK1; the disease is glioblastoma.